Efficacy and safety of beloranib for weight loss in obese adults: A randomized controlled trial

D.D. Kim; J. Krishnarajah; S. Lillioja; F. De Looze; J. Marjason; J. Proietto; S. Shakib; Bronwyn Stuckey; J.E. Vath; T.E. Hughes

doi:10.1111/dom.12457

Efficacy and safety of beloranib for weight loss in obese adults: A randomized controlled trial

D.D. Kim, J. Krishnarajah, S. Lillioja, F. De Looze, J. Marjason, J. Proietto, S. Shakib, Bronwyn Stuckey, J.E. Vath, T.E. Hughes

Research output: Contribution to journal › Article

38 Citations (Scopus)

Abstract

© 2015 John Wiley & Sons Ltd. Aim: To assess the efficacy, safety and tolerability of beloranib treatment for obesity. Methods: This phase II, double-blind, randomized study investigated the effects of beloranib suspension (0.6, 1.2 and 2.4mg) or placebo, administered subcutaneously, for 12weeks in 147 participants (primarily white women) with obesity. No diet or exercise advice was administered. Results: At week 12, beloranib resulted in dose-dependent progressive weight loss of -5.5±0.5, -6.9±0.6 and -10.9±1.1kg for the 0.6, 1.2 and 2.4mg beloranib doses, respectively, compared with -0.4±0.4kg with placebo (all p

Original language	English
Pages (from-to)	566-572
Journal	Diabetes, Obesity and Metabolism
Volume	17
Issue number	6
DOIs	https://doi.org/10.1111/dom.12457
Publication status	Published - 2015

Fingerprint

Cite this

Kim, D. D., Krishnarajah, J., Lillioja, S., De Looze, F., Marjason, J., Proietto, J., ... Hughes, T. E. (2015). Efficacy and safety of beloranib for weight loss in obese adults: A randomized controlled trial. Diabetes, Obesity and Metabolism, 17(6), 566-572. https://doi.org/10.1111/dom.12457

@article{7394c3fd035645a39bc5a08cd311482c,

title = "Efficacy and safety of beloranib for weight loss in obese adults: A randomized controlled trial",

abstract = "{\circledC} 2015 John Wiley & Sons Ltd. Aim: To assess the efficacy, safety and tolerability of beloranib treatment for obesity. Methods: This phase II, double-blind, randomized study investigated the effects of beloranib suspension (0.6, 1.2 and 2.4mg) or placebo, administered subcutaneously, for 12weeks in 147 participants (primarily white women) with obesity. No diet or exercise advice was administered. Results: At week 12, beloranib resulted in dose-dependent progressive weight loss of -5.5±0.5, -6.9±0.6 and -10.9±1.1kg for the 0.6, 1.2 and 2.4mg beloranib doses, respectively, compared with -0.4±0.4kg with placebo (all p",

author = "D.D. Kim and J. Krishnarajah and S. Lillioja and {De Looze}, F. and J. Marjason and J. Proietto and S. Shakib and Bronwyn Stuckey and J.E. Vath and T.E. Hughes",

year = "2015",

doi = "10.1111/dom.12457",

language = "English",

volume = "17",

pages = "566--572",

journal = "Diabets, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - Efficacy and safety of beloranib for weight loss in obese adults: A randomized controlled trial

AU - Kim, D.D.

AU - Krishnarajah, J.

AU - Lillioja, S.

AU - De Looze, F.

AU - Marjason, J.

AU - Proietto, J.

AU - Shakib, S.

AU - Stuckey, Bronwyn

AU - Vath, J.E.

AU - Hughes, T.E.

PY - 2015

Y1 - 2015

N2 - © 2015 John Wiley & Sons Ltd. Aim: To assess the efficacy, safety and tolerability of beloranib treatment for obesity. Methods: This phase II, double-blind, randomized study investigated the effects of beloranib suspension (0.6, 1.2 and 2.4mg) or placebo, administered subcutaneously, for 12weeks in 147 participants (primarily white women) with obesity. No diet or exercise advice was administered. Results: At week 12, beloranib resulted in dose-dependent progressive weight loss of -5.5±0.5, -6.9±0.6 and -10.9±1.1kg for the 0.6, 1.2 and 2.4mg beloranib doses, respectively, compared with -0.4±0.4kg with placebo (all p

AB - © 2015 John Wiley & Sons Ltd. Aim: To assess the efficacy, safety and tolerability of beloranib treatment for obesity. Methods: This phase II, double-blind, randomized study investigated the effects of beloranib suspension (0.6, 1.2 and 2.4mg) or placebo, administered subcutaneously, for 12weeks in 147 participants (primarily white women) with obesity. No diet or exercise advice was administered. Results: At week 12, beloranib resulted in dose-dependent progressive weight loss of -5.5±0.5, -6.9±0.6 and -10.9±1.1kg for the 0.6, 1.2 and 2.4mg beloranib doses, respectively, compared with -0.4±0.4kg with placebo (all p

U2 - 10.1111/dom.12457

DO - 10.1111/dom.12457

M3 - Article

VL - 17

SP - 566

EP - 572

JO - Diabets, Obesity and Metabolism

JF - Diabets, Obesity and Metabolism

SN - 1462-8902

IS - 6

ER -

Access to Document

10.1111/dom.12457